Navigation Links
KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
Date:11/7/2013

KB001-A, KB003 and KB004. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the company's limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that the company has initiated or plans to initiate; the company's dependence on Sanofi Pasteur for the development and commercialization of KB001-A; the company's ability to successfully complete further development of its programs; the uncertainties inherent in clinical testing, including time to enroll clinical studies; the timing, cost and uncertainty of obtaining regulatory approvals; the company's ability to protect the company's intellectual property; competition; changes in the regulatory landscape or the imposition of regulations that affect the company's products; and other factors listed under "Risk Factors" in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 1, 2013, the quarterly reports on Form 10-Q filed on May 14, 2013 and August 19, 2013, and the company's other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company has no obligation, and expressly disclaims any obligation to update, revise
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. Cell therapy using patients own bone marrow may present option for heart disease
2. Report presents designs for study of cancer risks near US nuclear facilities
3. Entomology 2012 to present 105 insect symposia in November
4. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
5. The Brain Prize 2012 is presented May 9th
6. Validity CTO to Present Natural ID Solutions for Improving Mobile Risk Management and User Experience at NFC Solutions Summit 2012
7. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
8. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
9. Coral reef experts to present latest coral reef science during July symposium
10. FirstMark Exhibiting and Presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium
11. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... David L. Kaplan, Ph.D., will head the brand-new, web-only ... editor-in-chief. With the first issue slated for publication in ... in the rapidly burgeoning field of biomaterials, the study ... living or biological systems. , "This new journal is ... field of biomaterials over the past decade and the ...
(Date:7/30/2014)... distance between two points is a straight line, and ... taking the familiar axiom to heart. , Though ... intense, with each racing for the chance to fertilize ... form cooperative groups that allow them to take a ... study, conducted by Heidi Fisher, a post-doctoral student working ...
(Date:7/30/2014)... the University of Helsinki and the Universitat Autnoma de ... morphological changes which have taken millions of years to ... development of mice teeth, induced in the laboratory, scientists ... those observed in the fossil registry of rodent species ... , To modify the development of their teeth, the ...
Breaking Biology News(10 mins):ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2When cooperation counts 2When cooperation counts 3Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2
... This news release is available in German . ... bees are dying and insect diversity is dwindling. Only recently, both ... decline, which jeopardises food security. The (lack of) pollination has thus ... habitats, and organic farming. ETH-Zurich researchers from the group headed ...
... CAMBRIDGE, Mass. , June 5, 2013  Emotient, the ... leading eye tracking and biometric software platform company, today ... and Yale University are the first customers of a ... analysis, eye tracking, EEG and GSR technologies. The combined ...
... new study finds that utilities aren,t rewarded for adopting ... make energy efficiency as attractive as renewables. The ... Environmental Law , examines key differences between energy efficiency ... professor at Oregon State University, outlines ways to increase ...
Cached Biology News:Pollination merely 1 production factor 2Pollination merely 1 production factor 3Pollination merely 1 production factor 4Emotient and iMotions Partner to Offer Unique Integrated Facial Expression Recognition, Bio Sensor and Eye Tracking Solution for Usability, Gaming, Market and Academic/ Scientific Research 2Emotient and iMotions Partner to Offer Unique Integrated Facial Expression Recognition, Bio Sensor and Eye Tracking Solution for Usability, Gaming, Market and Academic/ Scientific Research 3Emotient and iMotions Partner to Offer Unique Integrated Facial Expression Recognition, Bio Sensor and Eye Tracking Solution for Usability, Gaming, Market and Academic/ Scientific Research 4Study finds disincentives to energy efficiency can be fixed 2
(Date:7/31/2014)... 31, 2014   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues, today ... results will be released on Thursday, August 7, 2014, ... and live webcast at 4:30 p.m. ET that afternoon. ...
(Date:7/31/2014)... July 31, 2014 Boston’s Adult Stem ... flush with innovative adult stem cell biotechnologies. Currently ... and has three additional patent applications currently under examination ... patented inventions address two of the most vexing problems ... Adult stem cells are difficult to identify; and ...
(Date:7/30/2014)... and PARIS , July 30, 2014 ... SAN and NYSE: SNY) today announced that the Companies ... (FDA) rare pediatric disease priority review voucher in connection ...  The priority review voucher entitles the holder to designate ... expedited 6-month review from the filing date instead of ...
(Date:7/30/2014)... FRANCISCO , July 30, 2014 ... Congress evaluated the safety and efficacy of CSL ... rejection following kidney transplants in highly sensitized patients. ... inhibitor of the complement system. The ... in significant increases in the levels of complement ...
Breaking Biology Technology:BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... & Burling represented AstraZeneca in its $1.26 billion ... will pay $32 per share for all of ... (Logo: http://photos.prnewswire.com/prnh/20120423/CL92331LOGO  ) AstraZeneca ... primary focus on the discovery, development and commercialization ...
...  Melanie Pita, J.D., will offer her expert perspective ... hospitals as she presents "EHRs: Meaningful Use & ... Conference, being held  April 24-26, 2012, at the ... During the presentation, Pita, who serves ...
... Inc., a leading innovator of new life science tools, today ... of its innovative portable PCR system. The F1-12 system is ... high speed and sensitivity in a fully portable format. ... Standard Fast" speed levels delivering 30-cycle PCR amplification within ...
Cached Biology Technology:Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences 2Prognosis HIS Executive Slated To Offer EHR Advice At Illinois Rural Health Association Conference 2Ahram Biosystems Announces Launch of the New Economy Model F1-12 of Its Palm PCR Series 2
... Gasket slide kit (1x 22K gasket/slide) G2534-60003 ... or Gasket slide kit (2x 11K ... slides offered in either 11K or 22K microarray feature ... gaskets are carefully fabricated and batch tested to ensure ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... locking design in ice/water bath This ... number, created to easily match Cornings ... yet, please order under the old ... service for assistance. ID clarifier: rack ...
... Microarray Kit (V2), 2 x 11K ... expression of many thousands of yeast ... important biological processes. Each microarray contains ... ORFs from the S288C strain of ...
Biology Products: